Inactive Instrument

Endologix, Inc.

ELGXQ

US29266S3040

Medical Equipment, Supplies & Distribution

Endologix, Inc. Provides Revenue Guidance for the First Quarter of 2020

February 19, 2020 at 09:30 pm

Endologix, Inc. provided revenue guidance for the first quarter of 2020. For the first quarter of 2020, the company expects a revenue of at least $30 million.

Latest news about Endologix, Inc.

Endologix LLC Announces Online Publication of the One-Year Results of the DETOUR2 Trial in the Journal of Vascular Surgery	05-13	CI
Endologix LLC Appoints Mike Mathias as Chief Commercial Officer	03-05	CI
Endologix LLC Announces That Art Taylor Joins Board of Directors	01-25	CI
Endologix LLC Appoints Scott Ward Joins Board of Directors	01-09	CI
Endologix LLC Announces Appointment of Scott Ward as Board of Directors	01-09	CI
Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System	12-27	CI
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session	11-02	CI
Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System	07/09/23	CI
Endologix LLC Appoints Lucas Buchanan to its Board of Directors	24/08/23	CI
Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease	18/07/23	CI
Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting	15/06/23	CI
Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad	08/06/23	CI
Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial	23/05/23	CI
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session	11/11/22	CI
Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial	03/11/22	CI
Endologix LLC Announces the Elevate	20/10/22	CI
Endologix LLC Submits Premarket Approval Application to FDA for the DETOUR System	10/10/22	CI
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting	23/06/22	CI
Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA	23/11/21	CI
Endologix Appoints Dr. Matthew Thompson as CEO	16/11/21	CI
Endologix, Inc. Announces Board and Executive Changes	16/11/21	CI
Endologix LLC Initiates Randomized Study of ALTO® Abdominal Stent Graft System	29/09/21	CI
Endologix Llc Receives U.S. Food and Drug Administration Breakthrough Device Designation for ChEVAS System	19/07/21	CI
Endologix Llc Announces Launch of Alto Abdominal Stent Graft System in Canada and Argentina	11/05/21	CI
Endologix, Inc. acquired PQ Bypass, Inc. for approximately $300 million.	12/04/21	CI

Endologix, Inc. develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. The Company's products are designed for the minimally-invasive endovascular treatment of abdominal aortic aneurysms (AAA). Its AAA products are developed on one of two platforms: traditional minimally-invasive endovascular aneurysm repair (EVAR) or endovascular aneurysm sealing (EVAS), the Company's solution for sealing the aneurysm sac while maintaining blood flow. The Company's EVAR products include the AFX Endovascular AAA System (AFX System), the VELA Proximal Endograft (VELA) and the Ovation Abdominal Stent Graft System (Ovation System). The Company's EVAS product is the Nellix Endovascular Aneurysm Sealing System (the Nellix EVAS System).

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Medical Devices & Implants

	1st Jan change	Capi.
STRYKER CORPORATION	+15.11%	131B
SMITH & NEPHEW PLC	-8.47%	11.05B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-11.46%	7.71B
GLAUKOS CORPORATION	+40.89%	5.67B
INSPIRE MEDICAL SYSTEMS, INC.	-19.54%	4.95B
AXONICS, INC.	+8.12%	3.43B
ENOVIS CORPORATION	-19.67%	2.46B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-15.68%	1.97B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-15.34%	1.85B

Medical Devices & Implants

Endologix, Inc.

Equities

ELGXQ

US29266S3040

Medical Equipment, Supplies & Distribution

Endologix, Inc. Provides Revenue Guidance for the First Quarter of 2020

Latest news about Endologix, Inc.

Chart Endologix, Inc.

Company Profile

Sector Medical Devices & Implants